ATEMPT 2.0: Adjuvant T-DM1 vs TH (NCT04893109)

🧪 Interventions in This Study

• trastuzumab-emtansine (DRUG)
• Trastuzumab SC (DRUG)
• Paclitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (53 Sites)

Showing the first 25 of 53 sites.

• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• Smilow Cancer Hospital Care center at Derby — Derby, Connecticut
• Smilow Cancer Hospital Care center at Fairfield — Fairfield, Connecticut
• Smilow Cancer Hospital Care center at Glastonbury — Glastonbury, Connecticut
• Smilow Cancer Hospital Care center at Greenwich — Greenwich, Connecticut
• Smilow Cancer Hospital Care center at Guilford — Guilford, Connecticut
• Smilow Cancer Hospital Care center at St. Francis — Hartford, Connecticut
• Smilow Cancer Hospital Care center at Long Ridge — Long Ridge, Connecticut
• Yale Cancer Center at Yale University School of Medicine — New Haven, Connecticut
• Smilow Cancer Hospital Care center at North Haven — North Haven, Connecticut
• Stamford Hospital — Stamford, Connecticut
• Smilow Cancer Hospital Care center at Torrington — Torrington, Connecticut
• Smilow Cancer Hospital Care center at Trumbull — Trumbull, Connecticut
• Smilow Cancer Hospital Care center at Waterbury — Waterbury, Connecticut
• Smilow Cancer Hospital Care center at Waterford — Waterford, Connecticut
• Miami Cancer Institute/Baptist Hospital of Miami — Miami, Florida
• Miami Cancer Institute - Plantation (MCIP) — Plantation, Florida
• The University of Chicago Medical Center — Chicago, Illinois
• Indiana University Health Joe & Shelly Schwarz Cancer Center — Carmel, Indiana
• IU Health North Hospital — Carmel, Indiana
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
• Indiana University Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
• Eastern Maine Medical Center (Northern Light) — Brewer, Maine
• New England Cancer Specialists — Scarborough, Maine
• Beth Israel Deaconess Medical Center — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (617) 632-2335

Email: sara_tolaney@dfci.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer

• S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
• Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
• A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
• ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California

Explore by condition: All Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.